Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

Core Insights - VolitionRx Limited has published findings from its 'NETs in sepsis management' symposium, indicating that Nu.Q® NETs can predict patients at higher risk of deteriorating from sepsis [1][5] Group 1: Research Findings - The symposium presented results from three independent studies conducted in France, Germany, and the Netherlands, involving over 3,000 sepsis patients [2] - All studies utilized Volition's Nu.Q® NETs test to measure circulating H3.1 nucleosomes in the bloodstream, which serve as a surrogate marker for Neutrophil Extracellular Traps (NETs) [2] Group 2: Clinical Implications - Elevated levels of circulating H3.1 nucleosomes in sepsis patients are associated with a dysregulated immune response and increased risks of mortality, renal failure, respiratory failure, multi-organ failure, and septic shock [3] - The use of Nu.Q® NETs to measure elevated H3.1 levels could significantly enhance sepsis management, allowing for timely interventions to improve patient outcomes [5] Group 3: Commercialization Efforts - Volition is actively seeking to commercialize Nu.Q® NETs, with the findings from the studies supporting ongoing licensing discussions with key industry stakeholders [5] - The company aims to introduce Nu.Q® NETs into hospitals, potentially transforming sepsis treatment and improving survival rates and quality of life for survivors [4]